Literature DB >> 20222179

Rituximab maintenance for follicular lymphoma.

Liat Vidal, Anat Gafter-Gvili, Ofer Shpilberg.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20222179     DOI： 10.1038/nrclinonc.2009.161-c1

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  6 in total

1.  Hematology: The case against rituximab maintenance.

Authors:  Bruce D Cheson
Journal:  Nat Rev Clin Oncol       Date:  2009-11       Impact factor: 66.675

2.  Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial.

Authors:  Marinus H J van Oers; Richard Klasa; Robert E Marcus; Max Wolf; Eva Kimby; Randy D Gascoyne; Andrew Jack; Mars Van't Veer; Andrej Vranovsky; Harald Holte; Martine van Glabbeke; Ivana Teodorovic; Cynthia Rozewicz; Anton Hagenbeek
Journal:  Blood       Date:  2006-07-27       Impact factor: 22.113

3.  Rituximab maintenance treatment of relapsed/resistant follicular non-Hodgkin's lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study.

Authors:  Marinus H J van Oers; Martine Van Glabbeke; Livia Giurgea; Richard Klasa; Robert E Marcus; Max Wolf; Eva Kimby; Mars van t Veer; Andrej Vranovsky; Harald Holte; Anton Hagenbeek
Journal:  J Clin Oncol       Date:  2010-05-03       Impact factor: 44.544

4.  Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule.

Authors:  Michele Ghielmini; Shu-Fang Hsu Schmitz; Sergio B Cogliatti; Gabriella Pichert; Jörg Hummerjohann; Ursula Waltzer; Martin F Fey; Daniel C Betticher; Giovanni Martinelli; Fedro Peccatori; Urs Hess; Emanuele Zucca; Roger Stupp; Tibor Kovacsovics; Claudine Helg; Andreas Lohri; Mario Bargetzi; Daniel Vorobiof; Thomas Cerny
Journal:  Blood       Date:  2004-02-19       Impact factor: 22.113

Review 5.  Rituximab maintenance for the treatment of patients with follicular lymphoma: systematic review and meta-analysis of randomized trials.

Authors:  Liat Vidal; Anat Gafter-Gvili; Leonard Leibovici; Martin Dreyling; Michele Ghielmini; Shu-Fang Hsu Schmitz; Amos Cohen; Ofer Shpilberg
Journal:  J Natl Cancer Inst       Date:  2009-02-10       Impact factor: 13.506

6.  Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: results of the randomized phase III ECOG1496 Study.

Authors:  Howard Hochster; Edie Weller; Randy D Gascoyne; Thomas M Habermann; Leo I Gordon; Theresa Ryan; Lijun Zhang; Natalia Colocci; Stanley Frankel; Sandra J Horning
Journal:  J Clin Oncol       Date:  2009-03-02       Impact factor: 44.544
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.